Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$49.51
-0.47 (-0.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $4.0M · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.5B
P/E
25.7x
↑EV/EBITDA
15.3x
↑ROE
7.4%
↑Gross Margin
44.5%
↓Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.7%
FCF CAGR
—
FCF margin
0.3%
FCF / Net income
0.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.32B · net income $151.7M · FCF $4.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.32B | $1.32B | $1.10B | $1.09B | $833.8M |
| Net Income | $151.7M | $151.7M | $117.4M | $109.6M | $146.0M |
| EBITDA | $231.6M | $231.6M | $180.0M | $155.5M | $191.8M |
| EPS | 1.73 | 1.73 | 1.32 | 1.21 | 1.98 |
| Gross Margin | 44.5% | 44.5% | 41.3% | 40.0% | 44.4% |
| Operating Margin | 18.3% | 18.3% | 14.4% | 11.8% | 19.9% |
| Net Margin | 11.5% | 11.5% | 10.7% | 10.0% | 17.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.04 | 0.03 | 0.02 |
| Current Ratio | 7.43 | 7.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.0M | $4.0M | $70.0M | $-118.5M | $-8.5M |
| Returns | |||||
| ROE | 7.4% | 7.4% | 5.8% | 5.2% | 7.0% |
| Valuation | |||||
| P/E | 25.65 | 25.65 | 37.33 | 42.86 | 35.02 |
| EV/EBITDA | 15.29 | 15.29 | 18.67 | 22.38 | 19.02 |
| P/B | 2.12 | 2.12 | 2.16 | 2.25 | 2.46 |
| Growth & Yield | |||||
| Revenue Growth | 20.1% | 20.1% | 0.9% | 30.9% | — |
| EPS Growth | 31.1% | 31.1% | 9.1% | -38.9% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
36.4%
EPS terminal req.
$4.39
Spread vs growth
-5.4%
5Y implied EPS CAGR
25.2%
EPS terminal req.
$5.32
Spread vs growth
5.9%
10Y implied EPS CAGR
17.3%
EPS terminal req.
$8.56
Spread vs growth
13.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+19.4%
Start / end P/E
31.9x → 28.6x
EPS bridge
1.32 → 1.73
Residual
-3.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.